摘要
肺癌是全世界范围内死亡率最高的癌种,其诊疗进展一直备受关注。其中早中期可手术非小细胞癌(NSCLC)传统上采用以手术为主的综合治疗。随着免疫抑制剂(ICIs)的出现,NSCLC围术期治疗模式也随之改变。愈来愈多的研究表明“全程免疫疗法”可能产生更大获益,即“新辅助化疗联合免疫+手术+免疫单药辅助治疗”,俗称“夹心饼”、“三明治”治疗模式。文章对NSCLC围术期全程免疫疗法的由来及进展进行综述,以期为肺癌围术期综合治疗方案制定提供依据。
Lung cancer is the leading cancer in mortality in the world,and its diagnosis and treatment progress have been concerned.In the early and middle stages,operable non-small cell lung cancer(NSCLC)has traditionally been treated with a combination of operations.With the advent of immune checkpoint inhibitors(ICIs),perioperative treatment of NSCLC has also changed.More and more studies have shown that“wholecourse immunotherapy”may produce greater benefits,that is,“neoadjuvant chemotherapy combined with immunotherapy+surgery+immunoadjuvant therapy”,commonly known as“sandwich cake”and“sandwich”treatment mode.This article reviews the origin and progress of perioperative whole-course immunotherapy for NSCLC,in order to provide a basis for the formulation of perioperative comprehensive treatment for lung cancer.
作者
陈越
刘颖
蔡若雪
郭梦雅
彭炜惟
沙欢欢
方瑛
周国仁
CHEN Yue;LIU Ying;CAI Ruoxue;GUO Mengya;PENG Weiwei;SHA Huanhuan;FANG Ying;ZHOU Guoren(Department of Oncology,Jiangsu Cancer Hospital,Nanjing 210009,China)
出处
《中国肿瘤外科杂志》
CAS
2023年第6期591-598,共8页
Chinese Journal of Surgical Oncology
基金
国家自然科学基金项目(82273162)。
关键词
非小细胞肺癌
免疫检查点抑制剂
新辅助治疗
围术期治疗
临床研究
Non-small cell lung cancer
Immune checkpoint inhibitors
Neoadjuvant therapy
Perioperative treatment
Clinical research
作者简介
第一作者:陈越,女,硕士研究生在读,研究方向:肿瘤内科,Email:chenyuedmn163.com;通信作者:周国仁,男,博士,主任医师,研究方向:胸部恶性肿瘤、消化道恶性肿瘤的诊断和综合治疗,Email:zhouguoren888@163.com。
